ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

felzartamab

Also written as “Felzartamab”, “MOR202” and “TJ202 and Dexamethasone”.

Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma · Glomerulonephritis, Membranous · Myasthenia Gravis · Graves Disease, led by 3 companies.

Drug pageFelzartamab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 11, 202415 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only117 open or runningphase 3since Nov 11, 2024Oct 18, 2019Dec 1, 2026phase 3 · NCT06685757
TJ Biopharma30 open or runningphase 3since May 14, 2019Jan 15, 2019none ahead
Novartisits history only10 open or runningphase 2since Jul 29, 2011Jul 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TJ Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT03860038 · 113 enrolled · China, Taiwan
  2. May 14, 2019Phase 3 study in Multiple MyelomaNCT03952091 · 289 enrolled · China, Taiwan
  3. Dec 9, 2019Named felzartamabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, MOR202
  4. Nov 4, 2021Phase 1 study in Lupus Erythematosus, SystemicNCT05140824 · 1 enrolled · China

TargetBeta

CD38 →read by rule
“A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 24
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 3 TJ Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05140824Lupus Erythematosus, Systemic · China1TerminatedDec 14, 20221
NCT03952091Multiple Myeloma · China, Taiwan3CompletedJun 30, 2024289
NCT03860038Multiple Myeloma · China, Taiwan2CompletedJan 28, 2023113

How it is read

Names in the registry

  • “Felzartamab”, 9 entries
  • “MOR202”, 2 entries
  • “TJ202 and Dexamethasone”, 1 entry
  • “TJ202, Lenalidomide and Dexamethasone”, 1 entry
  • “TJ202 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.